TumorGen, our Partners, and the Fight Agains Metastasis in the NEWS
TumorGen presents poster at AACR - abstract#1333 - 17-Apr-2023
Dr. Peter Teriete will be presenting the latest data from TumorGen at the Annual AACR meeting in Orlando, FL.
"The data Peter will be presenting illustrates a very clear path on how TumorGen's technology can be utilized to identify anti-metastatic therapeutic targets. Identifying these previously unseen targets on metastatic cancer cell clusters (MCCCs) will lead to the development of new drugs than can prevent the spread of cancer! " says President and CEO Jeff Allen, PhD.
Click on the PDF icon to download the TumorGen AACR poster.
TumorGen invited to present at AACR in Orlando - 03-Feb-2023
TumorGen’s is presenting: "A novel and highly efficient biomimetic capture approach for the isolation and characterization of circulating metastatic cancer cell clusters from lung cancer patients" at the Annual AACR meeting in Orlando, FL in April 2023.
"We are excited to present our latest findings at the most impactful cancer forum there is." says President and CEO Jeff Allen, PhD.
TumorGen and PhenoVista capture the seeds that drive cancer metastasis - 08-Sep-2022
TumorGen’s microfluidic platform traps metastatic cancer cell clusters from lung cancer patients, creating new opportunities for anti-metastatic drug development.
Read the press release here:
TumorGen and PhenoVista join forces to illuminate metastasis - 16-Sep-2021
This collaboration will integrate TumorGen’s microfluidic capture system with PhenoVista’s cell cluster imaging platform to better understand how the spread of cancer is driven by the metastatic cancer cell clusters (MCCCs).
Read the press release here:
TumorGen proudly announces receiving a $390,000 SBIR grant from the National Cancer Institute focused on targeting metastasis - 26-Aug-2021
The funds will be used to validate our revolutionary biomimicry-immuno-capture technology, used to analyze circulating metastatic cancer cell clusters (MCCCs).
Read the press release here:
Darren ‘Ben’ Finlay, Ph.D. joins the TumorGen scientific team as a ‘Co-Investigator’ for the SBIR grant from the National Cancer Institute - 26-Aug-2021
We are thrilled to have Dr. Finlay join us as we begin to validate our unique microfluidic platform by analyzing whole blood samples from non-small cell lung cancer patients. The experience Ben brings to the project, specifically on multi-cellular cancer cell spheroids, will greatly expedite our progress. Dr. Ben Finlay is the Scientific Director of Tumor Analyses at Sanford Burnham Prebys Medical Discovery Institute (SBP). TumorGen is pleased to be working directly with SBP, an NCI-Designated Cancer Center and with Ben to bring a new focus on cancer metastasis.
https://www.sbpdiscovery.org/our-scientists/darren-ben-finlay-phd
TumorGen Advances In The San Diego Angel Conference Competition - 30-Jan-2020
TumorGen has been selected to present our technology and business opportunity to a select group of local investors on 6-Feb-2020. Dr. Peter Teriete will be presenting our vision on Fighting the Root Cause of Cancer and how we will change the way cancer is treated!
https://www.sandiego.edu/sdac/
TumorGen welcomes Dr. Ezra Cohen to the board of medical and scientific advisors - October 10, 2017
Dr. Ezra Cohen, a board-certified oncologist and cancer researcher at UCSD's Moores Cancer Center here in La Jolla joined TumorGen MDx's board of medical and scientific advisors. Dr. Cohen, a highly regarded clinical oncologist, has a strong focus on developing novel therapies and understanding mechanisms of sensitivity or resistance; cancer screening; and using medication and other agents to delay or prevent cancer (chemoprevention). His mission synergies well with our vision at TumorGen MDx and we are excited to add Dr. Cohen to our strong team.
Learn more about Dr. Cohen here: https://providers.ucsd.edu/details/22401/ezra-cohen-cancer-la_jolla
The TumorGen Breakthrough Team publishes it's first paper - June 18, 2019
Titled: "Design and production of a novel microfluidic device for the capture and isolation of circulating tumor cell clusters", it primarily describes the design of our microfluidic chip. The article, published by AIP Advances, can be found on-line at:
https://aip.scitation.org/doi/full/10.1063/1.5084736
If you would like a little more background on why we are focused on capturing cancer cell clusters, have a look at the press release on our paper via the link below:
https://medicalxpress.com/news/2019-06-microfluidics-device-captures-circulating-cancer.html
TumorGen launches new website - August 29, 2017
On August 29, 2017 TumorGen MDx went ‘live’ with its new and updated website. More information including videos illustrate continued progress on the Cancer Stem Cell Capture Chip (CSC3™) and our LiveCap MDx™ Process.
CureMatch Gets Seed Funding - August 15, 2017
CureMatch, a strategic partner with TumorGen MDx, announced they had raised a bridge round to a Series A financing
TumorGen Update STRIVE Award given to TumorGen - June 3, 2016
TumorGen MDx was awarded a prestigious Strive Award from Sanford Burnham Prebys Medical Discovery Institute.
This foundational seed funding allows TumorGen MDx to set focused resources on the next step in our fight against the root cause of cancer.
The San Diego Union-Tribune - November 4, 2014
News of our novel approach to capture cancer stem cells and the work we are doing with the Sanford Burnham Medical Research Institute plus San Diego State Univ. somehow made it to the San Diego Union Tribune.
Cancer Stem Cell Capture Chip (CSC3™) From TumorGen - March 28, 2014
This new device we are developing can capture extremely rare Cancer Stem Cells. We believe Cancer Stem Cells are the root cause of why tumors spread throughout the body. Capturing and genetically analyzing these cells may help stop cancer metastases.